Global firms look to India for APIs
PANAJI: Leaders from the world's leading companies held three days of talks in Goa on active pharma ingredients and intermediates, contract research, custom synthesis and partner selection for new chemical entities.
India is currently among the top five global manufacturers of active pharma ingredients (APIs). The production of APIs continues to swell with an increasing number of international companies making a beeline to India to meet their supply needs.
Growth consulting company Frost and Sullivan - which has offices in Mumbai and Chennai and was the organiser of the event - estimates the total production of bulk drugs and intermediates in India at $1.5-2 billion in 2004. Almost 70 per cent of the total bulk drug production is exported.
Held last week in Goa, the event was organised at the Leela, a luxury hotel in South Goa. "We had 50 participants, mainly from international companies who want to come to India to outsource. The goal was to help them see how the Indian market works," Frost and Sullivan spokesperson Surbhi Dedhia told the media here.
Nicholas Piramal India Ltd executive director (international) J C Saigal introduced the concept of custom manufacturing in India.
"Indian partnerships in the API and formulation development domain offer well-established reverse engineering skills, proven expertise in process development, synthesis, API and formulation development and inherent cost advantage," said Aditya Sapru, Director and Partner, Frost & Sullivan (India) director and partner Aditya Sapru.
June 14, 2005